BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21158496)

  • 1. Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol.
    Yamanouchi J; Hato T; Niiya T; Nakagawa K; Kumon Y; Fujiwara H; Yakushijin Y; Yasukawa M
    Platelets; 2011; 22(2):135-42. PubMed ID: 21158496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation.
    Yamamoto H; Takahashi K; Watanabe H; Yoshikawa Y; Shirakawa R; Higashi T; Kawato M; Ikeda T; Tabuchi A; Morimoto T; Kita T; Horiuchi H
    Circ J; 2008 Nov; 72(11):1844-51. PubMed ID: 18832777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
    Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
    Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.
    Fu Q; Yokoyama N; Takada K; Ishikawa S; Isshiki T
    Int Heart J; 2010; 51(5):303-7. PubMed ID: 20966600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets.
    Sudo T; Ito H; Kimura Y
    Platelets; 2003 Sep; 14(6):381-90. PubMed ID: 14602552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
    Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
    Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
    Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
    Thromb Haemost; 2013 Oct; 110(4):769-76. PubMed ID: 23903326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition.
    Jakubowski JA; Bourguet N; Boulay-Moine D; Sugidachi A; Yamaguchi S; Barragan P; Zhou C; Moulard M
    Thromb Haemost; 2012 Feb; 107(2):388-95. PubMed ID: 22186965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring.
    Satoh K; Fukasawa I; Kanemaru K; Yoda S; Kimura Y; Inoue O; Ohta M; Kinouchi H; Ozaki Y
    Thromb Res; 2012 Oct; 130(4):616-21. PubMed ID: 22728022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of platelet response to cilostazol with clinical outcome and CYP genotype in patients with cerebral infarction.
    Ikeda Y; Yamanouchi J; Kumon Y; Yasukawa M; Hato T
    Thromb Res; 2018 Dec; 172():14-20. PubMed ID: 30342278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
    Bidet A; Jais C; Puymirat E; Coste P; Nurden A; Jakubowski J; Nurden P
    Platelets; 2010; 21(2):94-100. PubMed ID: 20148735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis.
    Morel O; Faure A; Ohlmann P; Jesel L; Desprez D; Grunebaum L; Bareiss P
    Thromb Haemost; 2007 Oct; 98(4):896-9. PubMed ID: 17938817
    [No Abstract]   [Full Text] [Related]  

  • 18. Platelet VASP phosphorylation assessment in clopidogrel-treated patients: lack of agreement between Western blot and flow cytometry.
    Hezard N; Metz D; Garnotel R; Simon G; Mace C; Koebel P; Nguyen P
    Platelets; 2005 Dec; 16(8):474-81. PubMed ID: 16323337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
    Glenn JR; Dovlatova N; White AE; Dhillon K; Heptinstall S; Fox SC
    Thromb Haemost; 2014 Mar; 111(3):539-48. PubMed ID: 24258486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.